Samsung Biologics posts record profits after string of contract wins
Samsung Biologics, a biopharmaceutical contract manufacturer, posted an all-time-high operating profit of 1.11 trillion won ($829.3 billion) last year, up 13.22 percent on year, according to the company’s regulatory filing Wednesday.